CB06-036

DRUG2 trials

Sponsors

Shanghai Zhimeng Biopharma, Inc.

Conditions

Chronic Hepatitis bHealthy Volunteers

Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB06-036 in Subjects With Chronic Hepatitis B

CompletedNCT05828745

Shanghai Zhimeng Biopharma, Inc.Chronic Hepatitis b

Start: 2024-04-22End: 2025-02-18Updated: 2025-05-21

A Bridging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CB06-036 in Healthy Subjects in China

Shanghai Zhimeng Biopharma, Inc.Healthy Volunteers

Start: 2023-09-19End: 2023-12-29Target: 12Updated: 2023-10-26